DERMALGO
ActiveSummary
The computed 12-month bankruptcy probability of DERMALGO is 3.4% (moderate). The 2025 annual accounts show equity of €5,000 and a net result of €17,379. Equity is shrinking by about 24% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
11-01
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
30-09
Financial
Weakest financial yearnet €17,379 ▼65.9%
Net result drops to €17,379, the lowest in the series.
2024
19-12
NBB filing
Annual accounts filed
financial year 2024 · micro format
25-04
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
30-09
Financial
Highest result from 2021 to 2025net €85,851 ▲43.7%
Operating result €112,534, net result €85,851, both a record.
30-09
Financial
Liquidity more than doubledcurrent ratio 15.25
Current ratio from 6.31 to 15.25.
30-09
Financial
Equity above €150,000equity €176,029 ▲95.2%
A profit in every financial year since 2021 builds equity to €176,029.
25-04
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
30-09
Financial
Liquidity more than 11 timescurrent ratio 6.31
Current ratio from 0.56 to 6.31; short-term debt falls from €30,254 to €9,553.
2021
15-12
NBB filing
Annual accounts filed
financial year 2021 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.